Integris Medtech Eyes Rs 3,500-4,000 Crore IPO, Seeks Valuation Up to Rs 13,000 Crore
Integris Medtech, a medical technology company specializing in cardiac stents and medical devices, has filed preliminary papers with SEBI for an IPO. The offering aims to raise between Rs 3,500-4,000 crore through a fresh issue of Rs 925 crore and an offer for sale of 2.16 crore shares by promoters. The company plans to use the funds for debt repayment and general corporate purposes. Integris Medtech operates facilities in India, Germany, and the Netherlands, selling products in over 65 countries. The company reported a total income of Rs 1,959.58 crore in FY25, a 24% increase year-on-year, and turned profitable with a net profit of Rs 7.06 crore.
*this image is generated using AI for illustrative purposes only.
Integris Medtech, a prominent player in the medical technology sector, has taken a significant step towards going public by filing preliminary papers with the Securities and Exchange Board of India (SEBI) for an Initial Public Offering (IPO). The company, known for manufacturing cardiac stents and medical devices, is aiming to raise between Rs 3,500 crore and Rs 4,000 crore through this offering.
IPO Structure and Valuation
The proposed IPO comprises two components:
| Component | Details |
|---|---|
| Fresh Issue | Rs 925.00 crore |
| Offer for Sale | 2.16 crore shares by promoters |
| Target Valuation | Rs 11,000.00-13,000.00 crore |
The offer for sale includes shares from promoters Evercure Holdings, Gurmit Singh Chugh, and Punita Sharma. Additionally, the company is considering a pre-IPO placement of up to Rs 185.00 crore.
Use of Proceeds
The funds raised through the fresh issue are earmarked for:
- Debt repayment
- General corporate purposes
Company Overview
Integris Medtech, co-founded by Gurmit Singh Chugh and Punita Sharma, has established a strong presence in the medical devices industry:
- Manufacturing facilities in India, Germany, and the Netherlands
- Products sold in over 65 countries
Financial Performance
The company has shown impressive growth and profitability:
| Metric | FY25 | FY24 | Year-on-Year Change |
|---|---|---|---|
| Total Income | 1,959.58 | - | 24.00% increase |
| Net Profit | 7.06 | -4.80 | Turned profitable |
IPO Management
The following merchant bankers have been appointed to manage the IPO:
- ICICI Securities
- Axis Capital
- Citigroup Global Markets India
- IIFL Capital Services
This IPO marks a significant milestone for Integris Medtech and reflects the growing interest in India's medical technology sector. Investors will likely be keen to assess the company's growth potential, market position, and ability to innovate in the competitive medical devices industry.
19
